05.15.25 -- Unlock Agility And Efficiency In Biomanufacturing

Each of the major biologic manufacturing strategies — scale up, scale out, and continuous — presents specific advantages. As you consider the strategy that best pairs with your needs, examine a breakdown of each approach and the scenarios in which they excel before you select a path to commercialization. Plus, opting to partner with a manufacturer that provides all three allows you to pivot.

Many companies choose to manufacture mammalian cell culture-derived products using fed-batch technology. However, continuous manufacturing is more efficient than fed-batch manufacturing at the same production scale. Explore key considerations when choosing continuous bioprocessing and a continuous cell culture manufacturing platform.

Integrating advanced digitalization solutions and prioritizing data security can accelerate drug development while reducing costs and ensuring consistency across a global network. Through a focus on innovation, transparency, and security, FUJIFILM Diosynth Biotechnologies is aligning its operations with the future of the biopharma industry, setting new standards for efficiency, reliability, and regulatory compliance.

By aligning processes, equipment, and digital systems across a global network, kojoX, a standardized yet flexible modular biomanufacturing system, ensures seamless technology transfer, de-risks supply chains, and provides the agility biopharma companies need to deliver innovative therapies to patients faster and more reliably than ever before.